Roche Says Drug Helped Patients Reduce Blood-Sugar Levels, Weight in Trial — Live Feedhttps://www.live-feeds.com/feed/roche-says-drug-helped-patients-reduce-blood-sugar-levels-weight-in-trialContinuously updated, source-cited coverage. Roche Obesity Drug Enicepatide Hits Phase 2 Targets for Diabetes and Weight Losshttps://www.live-feeds.com/feed/roche-says-drug-helped-patients-reduce-blood-sugar-levels-weight-in-trialhttps://www.live-feeds.com/feed/roche-says-drug-helped-patients-reduce-blood-sugar-levels-weight-in-trial#u82065Thu, 24 Sep 2026 01:46:32 +0000Roche reported positive Phase 2 trial results for enicepatide, a GLP-1/GIP dual agonist targeting overweight patients with type 2 diabetes. Patients receiving the highest dose achieved an average weight loss of 15.5% and 90% reached a key blood sugar target after 48 weeks. Analysts describe the drug as competitive following this second mid-stage win. The treatment was originally acquired through Roche's purchase of Carmot Therapeutics.Why it mattersThe obesity and type 2 diabetes markets are growing exponentially. This drug enters a crowded field of GLP-1 receptor agonists aimed at metabo